Apotex Inc. v. Canada (Health), 2017 FC 857

JurisdictionFederal Jurisdiction (Canada)
CourtFederal Court (Canada)
Citation2017 FC 857
Date25 September 2017
    • This document is available in original version only for vLex customers

      View this document and try vLex for 7 days
    • TRY VLEX
4 practice notes
  • Federal Court Of Appeal Affirms Cancellation Of Reconsideration Of ANDS For Apo-Omeprazole
    • Canada
    • Mondaq Canada
    • 7 Mayo 2019
    ...satisfied that the question as framed by the Minister was reasonable. Link to decision: Apotex Inc. v Canada (Health), 2019 FCA 97 aff'g 2017 FC 857 About Norton Rose Fulbright Canada Norton Rose Fulbright is a global law firm. We provide the world's preeminent corporations and financial in......
  • Federal Court upholds cancellation of reconsideration of Apotex’s ANDS for Apo-omeprazole
    • Canada
    • LexBlog Canada
    • 9 Noviembre 2017
    ...questions, and the minister did not fetter her discretion in requiring bioequivalence. Case: Apotex Inc v Canada (Minister of Health), 2017 FC 857 Nature of case: Application for judicial review of refusal to reconsider an Abbreviated New Drug Submission (ANDS) Successful parties: The Minis......
  • Rx IP Update - October 2017
    • Canada
    • JD Supra Canada
    • 30 Octubre 2017
    ...omeprazole magnesium tablet regulatory submission: Apotex Inc v Canada (Health), 2017 FC 857. Apotex originally filed its Abbreviated New Drug Submission (ANDS) in 2000 and its submission was put on patent hold, which was later revoked because the ANDS lacked a high-fat study. Apotex re-sub......
  • Intellectual Property Weekly Abstracts Bulletin — Week Of October 2, 2017
    • Canada
    • Mondaq Canada
    • 5 Octubre 2017
    ...the Minister of Health's decision to cancel reconsideration of abbreviated new drug submission dismissed Apotex Inc. v. Canada (Health), 2017 FC 857 The Court dismissed Apotex's judicial review of the Minister of Health's decision to cancel the reconsideration of Apotex's submission in resp......
4 firm's commentaries
  • Federal Court Of Appeal Affirms Cancellation Of Reconsideration Of ANDS For Apo-Omeprazole
    • Canada
    • Mondaq Canada
    • 7 Mayo 2019
    ...satisfied that the question as framed by the Minister was reasonable. Link to decision: Apotex Inc. v Canada (Health), 2019 FCA 97 aff'g 2017 FC 857 About Norton Rose Fulbright Canada Norton Rose Fulbright is a global law firm. We provide the world's preeminent corporations and financial in......
  • Federal Court upholds cancellation of reconsideration of Apotex’s ANDS for Apo-omeprazole
    • Canada
    • LexBlog Canada
    • 9 Noviembre 2017
    ...questions, and the minister did not fetter her discretion in requiring bioequivalence. Case: Apotex Inc v Canada (Minister of Health), 2017 FC 857 Nature of case: Application for judicial review of refusal to reconsider an Abbreviated New Drug Submission (ANDS) Successful parties: The Minis......
  • Rx IP Update - October 2017
    • Canada
    • JD Supra Canada
    • 30 Octubre 2017
    ...omeprazole magnesium tablet regulatory submission: Apotex Inc v Canada (Health), 2017 FC 857. Apotex originally filed its Abbreviated New Drug Submission (ANDS) in 2000 and its submission was put on patent hold, which was later revoked because the ANDS lacked a high-fat study. Apotex re-sub......
  • Intellectual Property Weekly Abstracts Bulletin — Week Of October 2, 2017
    • Canada
    • Mondaq Canada
    • 5 Octubre 2017
    ...the Minister of Health's decision to cancel reconsideration of abbreviated new drug submission dismissed Apotex Inc. v. Canada (Health), 2017 FC 857 The Court dismissed Apotex's judicial review of the Minister of Health's decision to cancel the reconsideration of Apotex's submission in resp......

VLEX uses login cookies to provide you with a better browsing experience. If you click on 'Accept' or continue browsing this site we consider that you accept our cookie policy. ACCEPT